Regioselective hydroxylation of an antiarrhythmic drug, propafenone, mediated by rat liver cytochrome P450 2D2 differs from that catalyzed by human P450 2D6
- 14 June 2019
- journal article
- research article
- Published by Taylor & Francis in Xenobiotica
- Vol. 49 (11) , 1323-1331
Abstract
1. Propafenone, an antiarrhythmic drug, is a typical human cytochrome P450 (P450) 2D6 substrate used in preclinical studies. Here, propafenone oxidation by mammalian liver microsomes was investigated in vitro. 2. Liver microsomes from humans and marmosets preferentially mediated propafenone 5-hydroxylation, minipig, rat and mouse livers primarily mediated 4′-hydroxylation, but cynomolgus monkey and dog liver microsomes differently mediated N-despropylation. 3. Quinine, ketoconazole or anti-P450 2D antibodies suppressed propafenone 4′/5-hydroxylation in human and rat liver microsomes. Pretreatments with β-naphthoflavone or dexamethasone increased N-despropylation in rat livers. 4. Recombinant rat P450 2D2 efficiently catalysed propafenone 4′-hydroxylation in a substrate inhibition manner, comparable to rat liver microsomes, while human P450 2D6 displayed propafenone 5-hydroxylation. Human and rat P450 1A, 2C and 3A enzymes mediated propafenone N-despropylation with high capacities. 5. Carbon-4′ of propafenone docked favourably into the active site of P450 2D2 based on an in silico model; in contrast, carbon-5 of propafenone docked into human P450 2D6. 6. These results suggest that the major roles of individual P450 2D enzymes in regioselective hydroxylations of propafenone differ between human and rat livers, while the minor roles of P450 1A, 2C and 3A enzymes for propafenone N-despropylation are similar in livers of both species.Keywords
Funding Information
- Platform Project for Supporting Drug Discovery
- Life Science Research (Basis for Supporting Innovative Drug Discovery (JP18am0101121j0002)
- Young Scientists B (17K15520)
This publication has 17 references indexed in Scilit:
- Contributions of Ionic Interactions and Protein Dynamics to Cytochrome P450 2D6 (CYP2D6) Substrate and Inhibitor BindingJournal of Biological Chemistry, 2015
- Review article: the prevalence and clinical relevance of cytochrome P450 polymorphismsAlimentary Pharmacology & Therapeutics, 2007
- Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and inductionExpert Opinion on Drug Metabolism & Toxicology, 2006
- NONLINEAR PHARMACOKINETICS OF PROPAFENONE IN RATS AND HUMANS: APPLICATION OF A SUBSTRATE DEPLETION ASSAY USING HEPATOCYTES FOR ASSESSMENT OF NONLINEARITYDrug Metabolism and Disposition, 2005
- DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOSDrug Metabolism and Disposition, 2004
- SELECTIVITIES OF HUMAN CYTOCHROME P450 INHIBITORS TOWARD RAT P450 ISOFORMS: STUDY WITH cDNA-EXPRESSED SYSTEMS OF THE RATDrug Metabolism and Disposition, 2003
- Cytochromes P450 and experimental models of drug metabolismJournal of Cellular and Molecular Medicine, 2002
- Quinine is a more potent inhibitor than quinidine in rat of the oxidative metabolic routes of methoxyphenamine which involve debrisoquine 4-hydroxylaseXenobiotica, 1991
- The specificity of inhibition of debrisoquine 4-hydroxylase activity by quinidine and quinine in the rat is the inverse of that in manBiochemical Pharmacology, 1989
- The metabolic fate of2H-labelled propafenone in manEuropean Journal of Drug Metabolism and Pharmacokinetics, 1984